ZIOPHARM up 10% in early trading

|About: ZIOPHARM Oncology, Inc. (ZIOP)|By:, SA News Editor

Shares of ZIOPHARM Oncology (ZIOP +10.7%) get a post-report tailwind.

Investors like its collaboration with Intrexon (XON) for its RheoSwitch Therapeutic System, a method for modulating protein production in gene-based therapies.

The company's lead product, Ad-RTS-IL-12, a novel gene expression platform for interleukin-12, is currently in P2 trials for the treatment of melanoma and breast cancer.

Quick assets totaled $68.2M at years end and will be sufficient to fund operations into 2015's second quarter.

Earnings release